Vical posts herpes vaccine PhI/II failure, gutting shares

Vical posts herpes vaccine PhI/II failure, gutting shares

Vical posts herpes vaccine PhI/II failure, gutting shares
Pfizer Inc. Only limited clinical follow-up data are available to evaluate duration of protection, an important consideration when developing HZ vaccination policy recommendations. In the current study, we investigated the requirements for HSV-2 0ΔNLS vaccine-induced protection. While it collects those data, it’ll keep its focus on a late-stage cytomegalovirus vaccine program with Astellas, Samant said, with additional plans for a Phase I trial of an antifungal compound. Participants received two intramuscular doses of HZ/su or placebo 2 months apart and were followed for ≥30 months. The analyst warns that while Genocea expects GEN-003 to be able to tap into a potentially lucrative US market, the company will need to take measures to counteract the available antiviral treatments, which have strong familiarity and good overall profiles. Over 50% of the required 40 participants have passed the initial screening process and the first doses of the therapeutic vaccine are scheduled to be given this month.

It’s up against Agenus ($AGEN), which is also working to bring a herpes vaccine to market, though that company’s candidate is said to be disadvantaged both clinically and commercially compared to the Genocea vaccine, according to an analyst’s report last month. In his argument, GlobalData analyst Daian Cheng said that Agenus has cash flow issues–which the company denied–saying that it has shown interest in a partnership to further develop the jab.

You may also like